Opinion|Videos|September 29, 2026
COVID-19 in 2026: Navigating a Shifting Landscape at the Pharmacy Counter Deck
Author(s)Adam James, PharmD, Lauren Angelo
Experts discuss how pharmacists can apply shared clinical decision-making, address guidance fatigue, and build multi-vaccine programs as COVID-19 recommendations continue to evolve.
Advertisement
Episodes in this series
This MEDCast is dedicated to empowering pharmacists to play a more proactive and integrated role in the evolving management of bladder cancer, particularly as therapies such as enfortumab vedotin and antibody-drug conjugates reshape treatment paradigms across oncology practice. Through expert-driven discussions on patient identification, adverse event management, adherence, multidisciplinary collaboration, and real-world implementation, the series aims to equip pharmacy professionals with the clinical knowledge and practical strategies needed to improve treatment access, optimize safety, and enhance outcomes for patients with bladder cancer.
Advertisement
Related to this article
A single infusion reversed new-onset type 1 diabetes (T1D) in more than half of treated mice by strengthening regulatory T cells and driving autoreactive CD8+ T cells into a less destructive state.
A detailed LINKER-MM1 analysis found that cytokine release syndrome (CRS) with linvoseltamab occurred early, was predominantly low grade, and became less frequent with successive step-up and full doses.
Approval spans early and levodopa-treated disease; a 6-week titration and CYP3A interactions put pharmacists at the center of starting therapy.
In a Pharmacy Times interview, study coauthor William J. Peppard, PharmD, discusses the association between suzetrigine and fewer opioid refills after knee replacement, the limits of the evidence, and the access barriers pharmacists can help patients navigate.
The once-daily tablet is the third approved treatment for fibrodysplasia ossificans progressiva (FOP), with CYP3A4 and metformin interaction guidance.
Novo's topline phase 3 data show 12.4% weight loss with CagriSema 1.0 mg/1.0 mg in type 2 diabetes and 21.0% in adults with overweight or obesity.
Marissa Reigelman of US Pharmacopeia explains how single-country dependence on key starting materials, combined with low prices, has kept 5 critical injectable drugs in shortage for more than a decade.
An MRD-guided strategy incorporating teclistamab-daratumumab intensification produced deep responses in newly diagnosed high-risk multiple myeloma, although infections affected more than three-quarters of treated patients.
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Approves Tavapadon, First D1/D5 Agonist for Parkinson Disease
2
CagriSema Tops Tirzepatide 5 mg for Weight Loss in REIMAGINE 5
3
Engineered Stem Cell Therapy Reverses New-Onset T1D in Mice by Reprogramming T Cells
4
CKD Prevalence Unmoved Despite Billions in Virtual Care
5